JO3820B1 - أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها - Google Patents

أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها

Info

Publication number
JO3820B1
JO3820B1 JOP/2013/0131A JOP20130131A JO3820B1 JO 3820 B1 JO3820 B1 JO 3820B1 JO P20130131 A JOP20130131 A JO P20130131A JO 3820 B1 JO3820 B1 JO 3820B1
Authority
JO
Jordan
Prior art keywords
span
rtl
dir
antibodies
fel
Prior art date
Application number
JOP/2013/0131A
Other languages
English (en)
Inventor
Andrew J Murphy
Jamie Orengo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3820(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3820B1 publication Critical patent/JO3820B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بتوفير أجسام مضادة ترتبط بمولد حساسية من هرة، </span>Fel d1<span dir="RTL">، وتركيبات تتضمن تلك الاجسام المضادة، وأحماض نووية تشفر الأجسام المضادة وطرق لاستخدام تلك الأجسام المضادة. وفقا لنماذج معينة من الاختراع، تعد الأجسام المضادة عبارة عن أجسام مضادة أحادية النسيلة بشرية كاملة ترتبط بـ </span>Fel d1<span dir="RTL">، تعد الأجسام المضادة وفق الاختراع مفيدة للارتباط بمولد الحساسية </span>Fel d1<span dir="RTL"> في الجسم الحي، بما يمنع الارتباط بمولد الحساسية </span>Fel d1<span dir="RTL"> بـ </span>IgE<span dir="RTL"> متكون سلفا على سطح الخلايا البدينة أو الخلايا القاعدية. بذلك، تعمل الأجسام المضادة على منع إطلاق الهيستامين والعوامل الوسيطة الالتهابية الأخرى من الخلايا البدينة و/أو الخلايا القاعدية، بما يخفف من استجابة غير مستحبة لمسبب الحساسية من هرة في الأفراد المصابين بالحساسية. يمكن كذلك أن تكون الأجسام المضادة وفق الاختراع مفيدة لأغراض تشخيصية لتحديد ما إن كان المريض حساس لمسبب الحساسية من هرة </span>Fel d1<span dir="RTL">.</span>
JOP/2013/0131A 2012-05-03 2013-05-01 أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها JO3820B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642083P 2012-05-03 2012-05-03
US201261718044P 2012-10-24 2012-10-24
US201361783312P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3820B1 true JO3820B1 (ar) 2021-01-31

Family

ID=48326501

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0131A JO3820B1 (ar) 2012-05-03 2013-05-01 أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها

Country Status (33)

Country Link
US (6) US9079948B2 (ar)
EP (4) EP3978522B1 (ar)
JP (2) JP6400569B2 (ar)
KR (1) KR102185516B1 (ar)
CN (2) CN110240651B (ar)
AR (1) AR090914A1 (ar)
AU (2) AU2013256251C1 (ar)
BR (2) BR112014026852B1 (ar)
CA (1) CA2871077C (ar)
CY (2) CY1124023T1 (ar)
DK (2) DK2844672T3 (ar)
ES (3) ES2898372T3 (ar)
FI (1) FI3978522T3 (ar)
HR (3) HRP20211932T1 (ar)
HU (2) HUE049440T2 (ar)
IL (1) IL235121B (ar)
IN (1) IN2014DN08767A (ar)
JO (1) JO3820B1 (ar)
LT (3) LT2844672T (ar)
MX (2) MX377634B (ar)
MY (3) MY164101A (ar)
NZ (2) NZ733480A (ar)
PL (3) PL2844672T3 (ar)
PT (3) PT2844672T (ar)
RS (3) RS67417B1 (ar)
RU (1) RU2658491C2 (ar)
SG (3) SG11201406748QA (ar)
SI (3) SI3978522T1 (ar)
SM (3) SMT202500396T1 (ar)
TW (2) TW201803901A (ar)
UY (1) UY34782A (ar)
WO (1) WO2013166236A1 (ar)
ZA (3) ZA201407302B (ar)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
BR112014006390A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
RU2018105007A (ru) * 2015-09-08 2019-10-10 Университет Цюрих Композиции против аллергии на кошек
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP3558347B1 (en) * 2016-12-22 2026-01-21 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
CN110234354B (zh) * 2017-01-24 2023-09-12 雀巢产品有限公司 包含抗-fel d1抗体的组合物和用于减少人类对猫的过敏症的至少一种症状的方法
CN114075269A (zh) 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
KR20200115485A (ko) 2018-01-31 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
US12460270B2 (en) 2018-02-28 2025-11-04 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
BR112020015291B1 (pt) 2018-03-19 2023-09-26 Regeneron Pharmaceuticals, Inc Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US12103964B2 (en) 2018-05-18 2024-10-01 Cz Biohub Sf, Llc Methods of isolating allergen-specific antibodies from humans and uses thereof
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
KR20210053816A (ko) 2018-08-30 2021-05-12 리제너론 파마슈티칼스 인코포레이티드 단백질 복합체를 특성화하기 위한 방법
IL284471B2 (en) 2019-01-16 2025-01-01 Regeneron Pharma Methods for identifying free thiols in proteins
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
EP4653865A3 (en) 2019-09-24 2026-02-18 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
MX2022006236A (es) 2019-11-25 2022-06-22 Regeneron Pharma Formulaciones de liberacion sostenida con emulsiones no acuosas.
KR102544013B1 (ko) 2020-01-21 2023-06-19 리제너론 파마슈티칼스 인코포레이티드 당질화된 단백질의 전기영동을 위한 탈당질화 방법
US20220064270A1 (en) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
WO2022133135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CN116761880A (zh) 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
CA3207883A1 (en) 2021-03-03 2022-09-09 Xiaobin Xu Systems and methods for quantifying and modifying protein viscosity
JP2024509971A (ja) 2021-03-11 2024-03-05 アイジェニックス， インコーポレイテッド アレルギー応答を予測するための方法およびシステム
US20220309215A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
KR20240097864A (ko) 2021-10-26 2024-06-27 리제너론 파마슈티칼스 인코포레이티드 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
CN114113278B (zh) * 2021-11-24 2024-08-02 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
CA3245647A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS
AU2023289659A1 (en) 2022-06-23 2024-11-14 Regeneron Pharmaceuticals, Inc. Methods of identifying and evaluating cat allergy gene signatures in a subject by determining a stratified score based on gene expression
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
WO2024178213A2 (en) 2023-02-22 2024-08-29 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
KR20250165444A (ko) 2023-03-01 2025-11-25 리제너론 파마슈티칼스 인코포레이티드 항-fel d1 항체 제형
EP4688165A1 (en) 2023-03-31 2026-02-11 ALK-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117069865B (zh) * 2023-10-12 2024-03-01 中国农业科学院饲料研究所 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN117964767B (zh) * 2024-03-29 2024-08-06 北京恩泽康泰生物科技有限公司 抗rage抗体、细胞外囊泡及其制备方法和应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
CA2128331A1 (en) 1992-01-21 1993-07-22 Julia L. Greenstein Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
AU5958494A (en) * 1992-12-21 1994-07-19 Tanox Biosystems, Inc. Allergen-specific iga monoclonal antibodies and related products for allergy treatment
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7767212B2 (en) * 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
GB0513878D0 (en) * 2005-07-06 2005-08-10 Mars Inc Cat allergen
WO2007065633A1 (en) 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
WO2007113633A2 (en) 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1921142A1 (en) * 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2139924B1 (en) * 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
EP2666787B1 (en) * 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2162133T3 (pl) * 2007-07-09 2017-03-31 Nestec S.A. Sposoby zmniejszania alergii wywoływanych przez alergeny środowiskowe
KR101709488B1 (ko) * 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
EP3558347B1 (en) 2016-12-22 2026-01-21 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies

Also Published As

Publication number Publication date
ES2780392T3 (es) 2020-08-25
ZA202005273B (en) 2023-11-29
JP2015523962A (ja) 2015-08-20
KR20150005666A (ko) 2015-01-14
EP3978522A3 (en) 2022-07-06
HRP20211932T1 (hr) 2022-03-18
HUE049440T2 (hu) 2020-09-28
JP6603269B2 (ja) 2019-11-06
ZA201407302B (en) 2021-08-25
CN110240651B (zh) 2024-03-08
SI2844672T1 (sl) 2020-07-31
US20160376358A1 (en) 2016-12-29
DK2844672T3 (da) 2020-04-20
TW201406779A (zh) 2014-02-16
MY181422A (en) 2020-12-21
AU2013256251B2 (en) 2018-04-12
US20150299303A1 (en) 2015-10-22
RS62636B1 (sr) 2021-12-31
RS67417B1 (sr) 2025-12-31
US20180305446A1 (en) 2018-10-25
SI3660047T1 (sl) 2021-12-31
MX2020003864A (es) 2020-08-13
TW201803901A (zh) 2018-02-01
LT3660047T (lt) 2021-11-10
US12252530B2 (en) 2025-03-18
NZ701124A (en) 2017-07-28
SMT202200014T1 (it) 2022-03-21
PL2844672T3 (pl) 2020-08-10
IL235121B (en) 2019-06-30
ES2898372T3 (es) 2022-03-07
EP4653056A2 (en) 2025-11-26
CY1124023T1 (el) 2022-03-24
JP2017153491A (ja) 2017-09-07
EP3660047B1 (en) 2021-10-13
CA2871077A1 (en) 2013-11-07
RS60282B1 (sr) 2020-06-30
EP3978522A2 (en) 2022-04-06
FI3978522T3 (fi) 2025-11-13
RU2014148502A (ru) 2016-06-27
HRP20251429T1 (hr) 2026-01-02
ZA202202846B (en) 2023-11-29
DK3978522T3 (da) 2025-10-27
WO2013166236A1 (en) 2013-11-07
SG10201608378UA (en) 2016-11-29
SG11201406748QA (en) 2014-11-27
PL3660047T3 (pl) 2022-02-14
JP6400569B2 (ja) 2018-10-03
UY34782A (es) 2013-11-29
AU2013256251C1 (en) 2018-08-23
AU2018203087B2 (en) 2020-03-12
RU2658491C2 (ru) 2018-06-21
US9475869B2 (en) 2016-10-25
SG10202102919XA (en) 2021-05-28
CN104411719A (zh) 2015-03-11
HRP20200652T1 (hr) 2020-07-10
AU2013256251A1 (en) 2014-11-06
CA2871077C (en) 2021-08-17
CY1124819T1 (el) 2022-11-25
EP2844672B1 (en) 2020-02-12
US9079948B2 (en) 2015-07-14
CN110240651A (zh) 2019-09-17
MY195564A (en) 2023-02-02
AU2018203087A1 (en) 2018-05-24
LT3978522T (lt) 2025-11-25
MX377634B (es) 2025-03-10
TWI644921B (zh) 2018-12-21
US10047152B2 (en) 2018-08-14
AR090914A1 (es) 2014-12-17
PL3978522T3 (pl) 2026-01-05
SI3978522T1 (sl) 2025-11-28
NZ733480A (en) 2019-03-29
CN104411719B (zh) 2019-05-14
US20130295097A1 (en) 2013-11-07
PT2844672T (pt) 2020-04-30
US10047153B2 (en) 2018-08-14
EP3660047A1 (en) 2020-06-03
US11174305B2 (en) 2021-11-16
EP3978522B1 (en) 2025-10-01
IN2014DN08767A (ar) 2015-05-22
IL235121A0 (en) 2014-12-31
MX2014013371A (es) 2015-02-05
MY164101A (en) 2017-11-30
PT3660047T (pt) 2021-11-30
KR102185516B1 (ko) 2020-12-02
HK1202123A1 (en) 2015-09-18
EP2844672A1 (en) 2015-03-11
BR112014026852A2 (pt) 2017-07-18
BR122019023685B1 (pt) 2023-01-17
ES3049982T3 (en) 2025-12-19
LT2844672T (lt) 2020-04-10
SMT202000241T1 (it) 2020-07-08
US20170210790A1 (en) 2017-07-27
US20220025029A1 (en) 2022-01-27
SMT202500396T1 (it) 2025-11-10
BR112014026852B1 (pt) 2023-01-03
HUE057062T2 (hu) 2022-04-28
AU2018203087B9 (en) 2020-03-26
PT3978522T (pt) 2025-10-17

Similar Documents

Publication Publication Date Title
JO3820B1 (ar) أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
MX2023000390A (es) Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.
UA111340C2 (uk) Антитіло, яке специфічно зв&#39;язується з tnf-альфа людини
Terzieva et al. Early pregnancy human decidua is enriched with activated, fully differentiated and pro-inflammatory gamma/delta T cells with diverse TCR repertoires
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
UA104663C2 (xx) Антитіло, що зв&#39;язує cd127$антитело, связывающее cd127
EA201890907A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
EA201370081A1 (ru) Антитела к cd48 и их применение
PT2905030T (pt) Anticorpos humanos que ligam ao gene de ativação de linfócitos 3 (lag-3) e utilizações dos mesmos
UA117341C2 (uk) Кліщова композиція, яка включає хижого кліща та іммобілізовану жертву, що контактує зі стримуючим розвиток грибків агентом, і способи та застосування, пов&#39;язані з використанням зазначеної композиції
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA37945B1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d&#39;utilisation associées
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
EP4556906A3 (en) A cell mediated immune response assay with enhanced sensitivity
CN104853774A8 (zh) Il-20拮抗剂用于治疗肝脏疾病
CN110636857A8 (zh) 人红富铁激素的抗体及其用途
BR112013023513A2 (pt) anticorpos que ligam tgf-alfa e epiregulina
AR117721A2 (es) Anticuerpos humanos para fel d1 y métodos para usarlos
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Suzuki et al. Basic and clinical immunology–3022. Inhibitory action of fexofenadine hydrochloride on mast cell activation in vitro
de León Muñoz Quality and culture of health
Grainger Immune modulation by parasitic nematodes
Autors et al. Of Bodies and Symptoms
TH167984A (th) แอนติบอดีพอลิเพพไทด์ที่แอนทาโกไนซ์ cd40l
TH136515A (th) แอนติบอดีของคนที่มีสัมพรรคภาพสูงต่อแองจิโอโพอิทิน-2-ของคน